What is the recommended dosage of Trelegy Ellipta (fluticasone furoate, umeclidinium, vilanterol) in puffs per day for Chronic Obstructive Pulmonary Disease (COPD) management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Trelegy Ellipta Dosing for COPD

The recommended dose of Trelegy Ellipta for COPD is 1 puff once daily, and exceeding this dose is not recommended due to increased risk of adverse effects. 1, 2

Standard Dosing Regimen

  • Trelegy Ellipta 100/25 mcg (fluticasone furoate 100 mcg/umeclidinium 62.5 mcg/vilanterol 25 mcg) is administered as 1 inhalation once daily by oral inhalation for COPD maintenance treatment. 1, 2

  • The medication should be used at the same time every day, and must not be used more than once every 24 hours. 1, 2

  • More frequent administration or a greater number of inhalations than the prescribed single daily dose is explicitly not recommended, as some patients are more likely to experience adverse effects with higher doses. 1

Administration Guidance

  • After inhalation, patients should rinse their mouth with water without swallowing to reduce the risk of oropharyngeal candidiasis. 1, 2

  • If shortness of breath occurs between doses, an inhaled short-acting beta2-agonist (such as albuterol) should be used for immediate relief, not additional doses of Trelegy. 1, 2

  • The median time to onset of bronchodilation is approximately 15 minutes, with individual variation in time to onset and degree of symptom relief. 2

Critical Dosing Pitfall

The single most important point is that Trelegy Ellipta is strictly a once-daily medication—never twice daily or more frequently. This differs from some older COPD inhalers that require twice-daily dosing, and confusion about this can lead to overdosing and increased adverse effects. 1, 2

Real-World Effectiveness Context

  • In usual care settings, once-daily Trelegy Ellipta has demonstrated clinically meaningful improvements in CAT scores (mean reduction of 2.6 units at 12 months) and FEV1 (mean improvement of 93 mL), with significant reductions in exacerbation rates. 3

  • Patient adherence to the once-daily regimen is associated with better clinical outcomes, reinforcing the importance of maintaining the prescribed single daily dose. 3

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.